Invivyd

IVVD

Biotechnology · Healthcare

Exchange

NASDAQ

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Good

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

Invivyd is a biotechnology company focused on developing antibody-based medicines to protect people from viral infections, particularly COVID-19. Its main products are lab-engineered antibodies designed to prevent or treat illness in people whose immune systems do not respond well to vaccines — such as organ transplant recipients or patients on certain medications. The company sells these treatments primarily in the United States through healthcare providers and hospital systems.

Invivyd earns revenue by selling its antibody products, though sales have been limited and the company is spending far more than it brings in, reflected in its deeply negative operating margin. It operates mainly in the US and is a small-cap company still in an early commercial stage. Its scientific expertise in antibody engineering gives it some differentiation, but the business faces significant risk from the shrinking demand for COVID-19 treatments, rapid virus mutation that can make antibodies less effective, and intense competition from larger pharmaceutical companies with greater resources.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+21.2% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

-16.7% YoY

YoY Growth Rate

Earnings declining

Insider Activity

15.2%ownership

↑ Rising

Insiders increasing their stake — aligned with shareholders

Cash Runway

~11 months

$160M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

Invivyd has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

91.1%

Premium pricing power — 91.1% gross margin

Profit after running costs

Operating Margin

-320.8%

Losing money on operations — -320.8%

Return on the money invested

ROCE

-62.1%

Weak — -62.1% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+26.3%

Fast-growing sales (+26.3% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-187.9%

Burning cash (-187.9%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial